<DOC>
	<DOC>NCT02931344</DOC>
	<brief_summary>This is a substudy to a randomised trial investigating the effect of liraglutide on body weight and pain in overweight or obese patients with knee osteoarthritis (NCT02905864). This substudy aims to investigate any changes in biomarkers associated with the initial 8-week weight loss intervention</brief_summary>
	<brief_title>Biomarkers in Obese Patients With Knee Osteoarthritis; Weight Loss</brief_title>
	<detailed_description>In the parent trial, patients will be subjected to an 8-week diet intervention phase including a low-calorie diet and dietetic counselling, after which they will be randomised to receive either liraglutide 3 mg or liraglutide 3 mg placebo as an add-on to dietetic guidance on re-introducing regular foods and a focus on continued motivation to engage in a healthy lifestyle.</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Same as parent trial (NCT02905864) Same as parent trial (NCT02905864)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Osteoarthrtis</keyword>
	<keyword>Obesity</keyword>
	<keyword>Liraglutide 3 mg</keyword>
	<keyword>Liraglutide</keyword>
	<keyword>Biomarkers</keyword>
</DOC>